InspireMD, Inc. (NSPR) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

On November 14, 2016, InspireMD, Inc. (the Company) issued a
press release announcing its financial and operating results for
the third fiscal quarter ended September 30, 2016. A copy of this
press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit
99.1, that is furnished to this Item 2.02 shall not be deemed to
be filed for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, and shall not be
incorporated by reference into any registration statement or
other document filed under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.

Item 8.01 Other Events.

On November 14, 2016, the Company issued a press release
announcing that it has received regulatory approval to
commercialize the CGuard^TM Embolic Prevention System
for the treatment of carotid artery disease in Russia. A copy of
the press release is attached hereto as Exhibit 99.2, and is
incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

* This exhibit is furnished to Item 2.02 and shall not be deemed
to be filed.

About InspireMD, Inc. (NSPR)